(Sharecast News) - Sanofi said on Monday that it has agreed to buy US biopharmaceutical firm Blueprint Medicines for $9.1bn.
Blueprint specialises in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases.

The deal includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE